Written by: Ellie Pranckevicius, FNP-BC, Aesthetic Nurse Practitioner & Aesthetic Injector | Facial Restoration & Regenerative Injectable Specialist, Mirror Plastic Surgery | Last updated: July 18, 2026
Key Takeaways
- Tirzepatide delivers greater average weight loss than semaglutide in SURMOUNT-5, with a 6.5 percentage-point absolute difference at 72 weeks.1
- BPC-157 has no human weight-loss trial data and is not FDA-approved for metabolic use, remaining on the FDA Category 2 restricted list.
- Semaglutide and tirzepatide require ongoing use, and stopping treatment leads to meaningful weight regain within about one year.
- GLP-3R and other compounded incretin options offer alternatives for patients who need different tolerability or metabolic profiles under medical supervision.
- Mirror Plastic Surgery provides lab-guided, concierge-level peptide protocols led by Ellie Pranckevicius, FNP-BC. Book your consultation for a personalized, evidence-based plan.
How Semaglutide and Tirzepatide Compare in SURMOUNT-5
The SURMOUNT-5 randomized controlled trial, published in the New England Journal of Medicine in 2025, enrolled 751 adults with obesity and no type 2 diabetes and compared maximum tolerated doses of tirzepatide (up to 15 mg weekly) against semaglutide (2.4 mg weekly) over 72 weeks. Tirzepatide produced a mean body weight reduction of 20.2% versus 13.7% for semaglutide, a 6.5 percentage-point absolute difference.1 A greater proportion of tirzepatide participants achieved ≥20% and ≥25% body weight loss compared with semaglutide.1
Tirzepatide was also superior on all five key secondary endpoints in SURMOUNT-5, including waist circumference reduction of 18.4 cm versus 13.0 cm.1 A 2026 meta-analysis of three head-to-head randomized studies confirmed tirzepatide’s superior weight reduction, with a pooled mean difference of −5.19 kg (p = 0.0002).1
Both agents require continuous administration to sustain weight loss, and discontinuation leads to substantial weight regain within 12 months.1 Tirzepatide activates both GLP-1 and GIP receptors, while semaglutide activates only the GLP-1 receptor. This dual mechanism helps explain tirzepatide’s greater average weight loss and its generally improved GI tolerability profile at equivalent efficacy doses.
To expand options for patients who plateau on standard doses, the FDA approved Wegovy HD on March 19, 2026. This 7.2 mg higher-dose semaglutide formulation is approved for weight loss and long-term weight maintenance in adults with obesity or overweight with at least one weight-related condition, broadening the semaglutide dose range.
| Peptide | Mean % Weight Loss (72–68 weeks, head-to-head or pivotal trial) | FDA Status (Weight Loss) | Primary Mechanism |
|---|---|---|---|
| Semaglutide (Wegovy 2.4 mg) | −13.7% at 72 weeks (SURMOUNT-5) | FDA-approved (Wegovy) | GLP-1 receptor agonist |
| Tirzepatide (Zepbound 15 mg) | −20.2% at 72 weeks (SURMOUNT-5) | FDA-approved (Zepbound) | Dual GLP-1/GIP receptor agonist |
| BPC-157 | No human weight-loss trial data | Not FDA-approved; Category 2 restricted | Tissue repair and inflammation modulation (preclinical) |
| GLP-3R (compounded) | No published head-to-head RCT data; available under medical supervision only | Compounded; not independently FDA-approved | Next-generation incretin-based signaling, with reported fewer GI effects and reduced muscle-wasting risk |
BPC-157 for Weight Loss: What the Evidence Actually Shows
BPC-157 is not a proven weight-loss tool and has no completed human clinical trials measuring fat-loss outcomes such as fat mass, waist circumference, or body fat percentage. It is not FDA-approved for weight management or any therapeutic use. As of early 2026, zero published human RCTs exist for BPC-157 in any indication. The first registered human trial (NCT07437547) began recruiting in February 2026 for acute hamstring muscle strain repair, not weight loss or metabolic outcomes.
BPC-157 is a synthetic 15-amino-acid peptide derived from a naturally occurring gastric juice protein, studied mainly for gastric mucosal protection and tissue repair in animal models. Its mechanism of action does not involve appetite regulation, thermogenesis, or direct fat-loss pathways. No peer-reviewed evidence shows meaningful visceral fat reduction in any species. Many commercial sites still market BPC-157 as a fat-loss peptide, despite an evidence base limited to animal and in vitro GI healing studies.
The FDA placed BPC-157 on its Category 2 list of bulk drug substances that pose significant safety risks in compounded preparations. The 2026 WADA Prohibited List bans BPC-157 under the S0 catch-all at all times for competitive athletes, with no Therapeutic Use Exemption. The FDA Pharmacy Compounding Advisory Committee plans to review BPC-157 and six other peptides on July 23–24, 2026. This review does not equal approval and does not validate weight-loss efficacy.
Mirror Plastic Surgery uses BPC-157 only within its current evidence base. Ellie includes it as part of the Glow Stack for systemic inflammation, tissue repair, and gut health, not as a weight-loss agent. She reviews each patient’s labs and goals before recommending any peptide protocol.
GLP-3R and Compounded Incretin Options at Mirror Plastic Surgery
GLP-3R is a newer-generation compounded peptide in the incretin family, closely related to the GLP-1 pathway. Compared with older GLP-1 formulations, GLP-3R is reported to cause fewer gastrointestinal side effects and a lower risk of muscle wasting. It is used for broader metabolic indications, including insulin resistance, weight management, and cardiovascular risk factors, and is available only under medical supervision at Mirror Plastic Surgery.
The broader obesity drug pipeline explains why these compounded options matter today. Retatrutide, a triple GLP-1/GIP/glucagon agonist from Eli Lilly, produced up to 24.2% body weight reduction at 48 weeks in Phase 2 and up to 28.7% in Phase 3 TRIUMPH-4 data.1 CagriSema (cagrilintide plus semaglutide) achieved 22.7% mean weight loss at 68 weeks in the REDEFINE 1 Phase 3 trial and was filed with the FDA in December 2025.1 These next-generation agents are not yet widely available, so medically supervised compounded options like GLP-3R help fill a real gap for patients who need alternatives now.
Book an appointment with Ellie to review whether GLP-3R or another supervised protocol fits your metabolic profile and weight-loss goals.
Side-Effect Profiles for Semaglutide, Tirzepatide, and BPC-157
| Peptide | Common GI Effects | GI-Related Discontinuation Rate | Other Documented Risks |
|---|---|---|---|
| Semaglutide (Wegovy 2.4 mg) | Nausea about 44% during dose escalation (STEP 1), plus vomiting, diarrhea, and constipation | Higher than tirzepatide in SURMOUNT-5 | Black-box warning for potential thyroid C-cell tumor risk, contraindicated with MTC or MEN2 history |
| Tirzepatide (Zepbound 15 mg) | Nausea 24–33% during dose escalation (SURMOUNT-1), plus vomiting, diarrhea, and constipation | Lower than semaglutide in SURMOUNT-5 | Black-box thyroid warning |
| BPC-157 | Occasional mild nausea (under 5%), injection-site reactions, headache (under 2%), and dizziness (under 2%) | No human discontinuation data available | Theoretical pro-angiogenic tumor promotion risk via VEGF/VEGFR2 upregulation, with human toxicity still uncharacterized, and WADA prohibition |
How Ellie Structures Safe, Effective Peptide Care
Ellie Pranckevicius, FNP-BC, oversees all peptide therapy and non-surgical aesthetics at Mirror Plastic Surgery. She is a board-certified Family Nurse Practitioner who earned her Bachelor’s in Health Science from Boston University, completed an aesthetics licensure program, and holds both her Bachelor’s and Master’s in Nursing from the University of South Florida. Her four years in the Neuroscience ICU at Tampa General Hospital built deep expertise in physiology, metabolic health, and complex patient management. This blend of critical-care nursing and esthetician training allows her to connect clinical science with aesthetic goals in every weight-loss protocol.
The checklist below covers the questions patients most often raise during a first consultation.
- Sourcing: Compounded versions of GLP-1 medications have shown quality concerns in independent lab testing. Mirror Plastic Surgery uses only reputable providers with rigorous batch testing and documented purity.
- Lab work: For weight-loss protocols, Ellie reviews or orders thyroid, liver, kidney, diabetes marker, and hormone panels before starting any plan. Lab results guide which peptide or combination fits your profile.
- Dosing safety: As of July 31, 2025, the FDA had received 605 adverse-event reports for compounded semaglutide and 545 for compounded tirzepatide, including dosing errors that led to hospitalizations. Supervised titration with ongoing monitoring sharply reduces this risk category.
- Outcomes after therapy stops: Given the significant weight regain that follows discontinuation, as detailed in the evidence section above, Ellie builds maintenance planning into every protocol from the start.
- Contraindications: Absolute contraindications for GLP-1 weight-loss peptides include active pancreatitis, family history of medullary thyroid cancer, MEN 2, active or recent cancer, pregnancy or breastfeeding, and age under 18. A thorough medical history review screens for all of these before any prescription.
- Ongoing support: Patients have direct text access to Ellie for questions, refill requests, and dose adjustments. Telemedicine appointments are available across Florida and in additional locations where permitted.
How Ellie Chooses Between Semaglutide, Tirzepatide, BPC-157, and GLP-3R
Evidence-based selection among these peptides depends on several patient-specific variables.
- Magnitude of weight-loss goal: Given tirzepatide’s superior outcomes in SURMOUNT-5, patients with higher weight-loss targets may benefit from its dual mechanism.
- GI tolerability history: Patients who stopped semaglutide due to GI intolerance sometimes tolerate tirzepatide after careful re-titration. GIP receptor activation can partially counter GLP-1-driven gastric motility effects.
- Cardiovascular risk profile: The SELECT trial, with 17,604 participants, showed a 20% reduction in major adverse cardiovascular events with semaglutide versus placebo. This gives semaglutide a larger long-term cardiovascular outcomes dataset than tirzepatide currently has.
- Muscle preservation: GLP-3R compounded protocols and adjunctive peptides such as Sermorelin and Ipamorelin may be considered for patients who prioritize muscle retention, under Ellie’s supervision and with appropriate lab monitoring.
- Regulatory and sourcing integrity: Semaglutide and tirzepatide are FDA-approved drugs that are not affected by the 2026 peptide reclassification process, while BPC-157 remains on the Category 2 restricted list as of mid-2026. Any protocol must reflect current regulatory status.
Putting the Evidence Together for Your Treatment Plan
In 2026, the clinical evidence hierarchy for medical weight-loss peptides is clear. Semaglutide and tirzepatide are supported by large, multi-year randomized controlled trials with well-characterized safety profiles and FDA approval. BPC-157 has no human weight-loss evidence and remains preclinical for all metabolic indications. Newer compounded options such as GLP-3R add tools for patients who need alternatives, but only within rigorous medical supervision that includes lab panels, dose titration, and ongoing monitoring.
Mirror Plastic Surgery’s concierge model, led by Ellie Pranckevicius, FNP-BC, provides that framework. Patients receive in-depth lab analysis, personalized protocol design, quality-assured sourcing, and direct practitioner access throughout treatment. Generic online sources cannot match this level of individualized, evidence-first care.
Book an appointment with Ellie to begin a lab-guided, medically supervised weight-loss protocol tailored to your physiology and goals.
Frequently Asked Questions
Is tirzepatide always the better choice over semaglutide for weight loss?
Tirzepatide produced greater average weight loss than semaglutide in the SURMOUNT-5 head-to-head trial, but the better choice still depends on individual factors. Semaglutide carries a larger cardiovascular outcomes dataset from the SELECT trial, discussed in the decision factors above, with demonstrated long-term cardiac benefits over about three years. Its long-term cardiovascular safety data are still expanding. Patients with a history of GI intolerance to semaglutide may tolerate tirzepatide better because of its dual GLP-1 and GIP mechanism, while others respond well to semaglutide at lower doses. The right choice requires a full medical history review, current lab work, and a clear discussion of goals, which Ellie provides during a Mirror Plastic Surgery consultation.
Can BPC-157 help with weight loss if I combine it with a GLP-1 medication?
No published human evidence supports BPC-157 as a weight-loss agent in any setting, including combination use with GLP-1 medications. BPC-157’s mechanism focuses on tissue repair, gut mucosal healing, and inflammation modulation, which differs from the appetite and metabolic pathways targeted by semaglutide and tirzepatide. Any indirect metabolic benefit from improved gut health remains theoretical in humans. At Mirror Plastic Surgery, BPC-157 is used within its validated evidence base as part of the Glow Stack for systemic inflammation, tendon and joint repair, and gut integrity support. It is not prescribed as a weight-loss adjunct, and Ellie explains clearly what the evidence does and does not support for each patient’s goals.
What happens to my weight if I stop taking semaglutide or tirzepatide?
Both semaglutide and tirzepatide require continuous use to sustain weight loss. As noted earlier, stopping these medications leads to significant weight regain within the first year because neither drug permanently resets the underlying metabolic set point. They manage appetite and glucose signaling only while active. This pattern resembles stopping other chronic disease medications, where the condition they control tends to return. Mirror Plastic Surgery builds maintenance planning into every protocol from the beginning. Ellie discusses realistic long-term expectations, potential transition strategies, and complementary lifestyle and peptide approaches during the initial consultation, so patients understand what to expect if therapy changes.
Why is medical supervision necessary for weight-loss peptides when I can buy them online?
Unregulated online peptide sources carry documented risks that supervised clinical care avoids. Independent lab testing has found mislabeling, improper dosing, or contamination in about 30% of peptide samples from gray-market sources, and compounded GLP-1 medications have shown quality concerns in independent testing. The FDA adverse event data cited earlier, including dosing errors that caused hospitalizations, highlight these dangers. Effective weight-loss peptide therapy also requires baseline lab panels to screen for contraindications, individualized dose titration, and ongoing monitoring of metabolic markers. Mirror Plastic Surgery delivers all of this through Ellie’s concierge model, including direct text access, telemedicine follow-up, and detailed lab review.
What is GLP-3R and how does it differ from semaglutide or tirzepatide?
GLP-3R is a newer-generation compounded peptide in the incretin family, related to the GLP-1 pathway that underlies both semaglutide and tirzepatide. Compared with older GLP-1 formulations, GLP-3R is reported to cause fewer gastrointestinal side effects, carry a lower risk of muscle wasting, and support broader metabolic indications such as insulin resistance and cardiovascular risk factors. Unlike semaglutide and tirzepatide, GLP-3R does not yet have large Phase 3 trial datasets and is available only through medically supervised compounding. It is one of several tools Ellie considers when designing a personalized protocol, especially for patients with prior GI intolerance to standard GLP-1 agents or specific muscle-preservation needs. A full consultation and lab review determine whether GLP-3R is appropriate for any individual patient.
Medical Disclaimer: The information in this article is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Individual results vary significantly based on genetics, health status, lifestyle, and the specific protocol used. Semaglutide and tirzepatide are FDA-approved prescription medications that carry boxed warnings and contraindications, and they must be prescribed and monitored by a licensed healthcare provider. BPC-157 is not FDA-approved for any therapeutic use and remains on the FDA Category 2 restricted list as of the publication date of this article (July 18, 2026). GLP-3R is a compounded option available only under medical supervision and is not independently FDA-approved. Regulatory status of compounded peptides can change, so consult a qualified provider for current guidance. All clinical statistics cited reflect published trial data at the time of writing and apply to study populations, not individual outcomes. Mirror Plastic Surgery services are available in St. Petersburg and Tampa, Florida, and remotely across the United States where permitted by law.
1 Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
Peptide therapy is intended for wellness and optimization purposes and is not prescribed to diagnose, treat, cure, or prevent disease unless specifically stated. Many peptides are not FDA-approved and may be used off-label. Some have limited long-term safety data, with a potential for unknown risks, complications, or desensitization with prolonged use.
